Open AccessGenomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study
Author(s) -
Nørøxe Dorte S.,
Yde Christina W.,
Østrup Olga,
Michaelsen Signe R.,
Schmidt Ane Y.,
Kinalis Savvas,
Torp Mathias H.,
SkjøthRasmussen Jane,
Brennum Jannick,
Hamerlik Petra,
Poulsen Hans S.,
Nielsen Finn C.,
Lassen Ulrik
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12790
Subject(s) - temozolomide , medicine , oncology , clinical trial , precision medicine , prospective cohort study , exome sequencing , bioinformatics , radiation therapy , pathology , biology , mutation , genetics , gene
Landscape of somatic copy number alterations, mutations, and fusions in selected genes in newly diagnosed glioblastoma patients. The most frequent aberrations occurred in PTEN, CDKN2A/B, EGFR, RB1, and NPAS3, and the most frequent mutations were in PTEN, TP53, NF1, RB1, and EGFR . One NTRK2 fusion and three FGFR3‐TACC3 fusions were identified.